We are IntechOpen, the world’s leading publisher of Open Access books
Built by scientists, for scientists

3,800
Open access books available

116,000
International authors and editors

120M
Downloads

154
Countries delivered to

TOP 1%
Our authors are among the most cited scientists

12.2%
Contributors from top 500 universities

WEB OF SCIENCE™
Selection of our books indexed in the Book Citation Index in Web of Science™ Core Collection (BKCI)

Interested in publishing with us?
Contact book.department@intechopen.com

Numbers displayed above are based on latest data collected.
For more information visit www.intechopen.com
1. Introduction

Genetic polymorphisms and mutations in drug metabolizing enzymes, transporters, receptors, and other drug targets (e.g., toxicity targets) are linked to inter-individual differences in the efficacy and toxicity of many medications as well as risk of genetic diseases. Validation of clinically important genetic polymorphisms and the development of new technologies to rapidly detect clinically important variants are critical issues for advancing personalized medicine.

Pharmacogenomics, which deals with heredity and response to drugs, is the scientific field that attempts to explain individual variability of drug responses and to search for the genetic basis of such variations or differences (Evans et al., 2001). The inter-individual variation in the rate of drug metabolism has been known for many years. Initially, the study of pharmacogenetics was only of academic interest, but today it is of major concern to the pharmaceutical industry as a means for documenting the metabolism of a new drug in development before registration. The knowledge of how a drug is metabolized and which enzymes are involved may help to predict drug-drug interactions and the rate at which individual patients may metabolize a specific drug. Such information is now required for registration by the U.S. Food and Drug Administration (FDA) and similar authorities (Salerno & Lesko, 2004a, 2004b). To improve drug safety, the FDA has started to update the labels and package inserts of previously approved drugs as new clinical and genetic evidence accrues (Frueh et al., 2008; Lesko, 2008).

The current important step is to incorporate pharmacogenomics data into routine clinical practice. As a means of implementing personalized medicine, it is critically important to understand the molecular mechanisms underlying inter-individual differences in the drug response, namely, pharmacological effect vs. side effect. The occurrence of personal variations in the response to a drug may result from many different causes, for example, genetic variations and expression levels of drug-targeted molecules, including membrane receptors, nuclear receptors, signal transduction components, and enzymes, as well as those of drug-metabolizing enzymes and drug transporters (Evans et al., 2001). Recently, tools such as next-generation sequencing technologies and genome-wide association studies (GWAS) have been used to uncover a number of variants that affect drug toxicity and efficacy as well as potential risk of diseases. The costs involved in carrying out GWAS and...
sequencing have been dropping dramatically, while providing data at an unprecedented rate. The GWAS approach has been applied for identifying genetic contributions to variations in drug response (The SEARCH Collaborative Group, 2008; Kamatani et al., 2010; Cooper et al., 2008; Schuldiner et al., 2009; Ge et al., 2009; Daly et al., 2009). As a result, there have been dramatic increases in our understanding of the mechanisms of drug action and of the genetic determinants responsible for variable responses to both rarely and widely used drugs, such as warfarin, tamoxifen, and clopidogrel.

Technologies are evolving to transform diagnostic devices for rapid genetic testing. Portable devices are being engineered for use in a range of settings to perform robust assays for the diagnosis of disease that will improve patient management, and result in greater convenience and speed to answer. The genetic diagnostics is a growing field that is gradually becoming more user-friendly with the introduction of portable devices and quicker nucleic acid detection. Successful genetic diagnostics require 4 major elements, such as rapid reaction, low cost, low energy consumption, and simple analysis (with minimal technical training and inclusion of controls but no off-instrument processing or reagent preparation). In this context, we decided to develop a point-of-care “POC” technology and to apply it to medical advances.

Development of personalized medicine including POC technology requires integration of various segments of biotechnology, clinical medicine, and pharmacology. A key requirement for advancing personalized medicine is the ability to rapidly and conveniently test for patients’ genetic polymorphisms and/or mutations. To address this urgent need, we have recently developed a rapid and cost-effective method, named Smart Amplification Process (SmartAmp), which enables us to detect genetic polymorphisms or mutations in target genes within 30 to 45 minutes under isothermal conditions that do not require DNA isolation and PCR amplification (Mitani et al., 2007; Mitani et al., 2009; Ishikawa et al., 2010; Aw et al., 2011; Ota et al., 2010; Lezhava et al., 2010; Toyoda et al., 2009; Aomori et al., 2009; Watanabe et al., 2007; Okada et al., 2010; Azuma et al., 2011). In this book chapter, we will present the technological development and clinical applications of the SmartAmp method.

2. SmartAmp method

The SmartAmp method was developed based on the principal concept that DNA amplification itself is the signal for detection of a genetic mutation or SNP. Differing from the widely-used PCR, the SmartAmp method is an isothermal DNA amplification reaction (Mitani et al., 2007; Mitani et al., 2009). In the SmartAmp method, the entire DNA amplification process requires five primers: turnback primer (TP), boost primer (BP), folding primer (FP), and two outer primers (OP1 and OP2) (Fig. 1). Primers are selected based on those algorithms considering the free energy, probability of base-pairing, product size range, optimal melting temperature, and product size range. The design of these primers contributes to the specificity of SmartAmp. In particular two primers (TP and FP) are critically important for the amplification process. The genomic sequence between the annealing sites of the TP and FP primers is the target region that will be amplified by the SmartAmp reaction. The other primers (BP, OP1, and OP2) are additionally employed to accelerate the process and enhance specificity.
Recent Advances in Pharmacogenomic Technology for Personalized Medicine

Fig. 1. Schematic illustration of five primers used for the SmartAmp method: turn-back primer (TP), boost primer (BP), folding primer (FP), and two outer primers (OP1 and OP2).

2.1 Molecular mechanism underlying isothermal DNA amplification

In isothermal DNA amplification by the SmartAmp method, the initial step of copying a target sequence from the genomic DNA is a prerequisite. FP and TP hybridize the template genomic DNA. Next, both products primed for the FP and TP are detached from template genomic DNA by strand-displacing DNA polymerase, whose extensions are primed by OP1 and OP2. Single-stranded DNA products, thus displaced, become templates in the second step for the opposing FP and TP. These single-stranded DNA products are generated by the strand-displacement activity of the DNA polymerase, being primed from the flanking region of OP primers adjacent to the target sequence. The resulting DNA products are referred to as “intermediate products”, IM1 and IM2, which play key roles in the subsequent amplification steps (Fig. 2).

Fig. 2. Formation of intermediate products in the initial step of the SmartAmp reaction. The priming events of the SmartAmp reaction generate two intermediates (i.e., IM1 and IM2).

The formation of those intermediate products (IM1 and IM2) is the rate-limiting step in SmartAmp-based isothermal DNA amplification. IM1 has the TP sequence at the 5’ end and the FP complementary sequence at the 3’ end; and IM2 is complementary to IM1 (Fig. 3).
The initial self-priming site on IM1 is the 3’-end of the FP sequence of IM1. Concatenated products of IM1 are synthesized by an elongation process termed pathway A. The characteristic feature of the products of pathway A is that the free 5’ and 3’ ends carry TP and its complementary sequence, forming long double stranded hairpin DNA. The initial self-priming elongation site on IM2 is located at the 3’ end of the TP sequence of IM2. Long concatenated DNA products are synthesized as in pathway A, but end products in pathway B are different. The long-hairpin DNA products of pathway B carry FP and its complementary sequence at the free 5’ and 3’ ends respectively. There is another elongation pathway which starts from the 3’ end of a free TP-primer that hybridizes to the looping structure of the TP complementary sequence, which is located at the intermediate region of the long products of pathway A. Thus, concatenated DNA products are formed in the SmartAmp reaction. The resulting DNA products could be detected by conventional agarose gel electrophoresis, where DNA ladder patterns represented the formation of concatenated DNA products (Mitani et al., 2007) (Fig. 3).

Fig. 3. The molecular mechanism underlying isothermal DNA amplification. Formation of concatenated DNA products in the SmartAmp reaction. Self-priming DNA synthesis from each of the intermediates, IM1 and IM2, creates hairpin molecules via pathway A or B. These structures lead to further self-primed DNA synthesis to create dimeric amplicons and then subsequently concatenated DNA products.

2.2 Molecular mechanism underlying SNP detection

To ensure the high fidelity of SNP detection by the SmartAmp method, exponential amplification of mis-primed DNA must be suppressed. In the original SmartAmp method,
this was achieved by adding either the mismatch binding protein (MutS) *Thermus aquaticus* (Mitani et al., 2009) or a competitive probe (Toyoda et al., 2009) to the reaction mixture. MutS inhibits background DNA from entering the amplification cycle by specifically binding to mis-primed amplification products (Fig. 4). In addition, a combination of the asymmetrical primers, i.e., TP and FP is used to minimize alternative mis-amplification pathways (Mitani et al., 2007).

The SmartAmp method utilizes *Aac* polymerase as a DNA polymerase with strand-displacement activity. This DNA polymerase is highly resistant to cellular contaminants and hence works directly on blood samples, just after a simple heat treatment (98°C, 3 min) to degrade RNA and denature proteins. This is a great advantage of the SmartAmp method over the commonly used PCR-based techniques that require careful DNA extraction. In the conventional method, the enzymatic activity of Taq DNA polymerase is easily inhibited by impurities.

### 2.3 Example of SNP detection by SmartAmp method

Clinical application of SmartAmp to practical SNP detection should be evaluated with clinical samples (either blood or genomic DNA) according to the principle of amplification versus non-amplification as compared to threshold values. The amount of DNA-
intercalating SYBR Green I dye during the reaction can be monitored in a real-time PCR system (e.g., Mx3000P), and thereby SNP typing can be determined by referring to the intensity of fluorescence.

Each SmartAmp2 reaction is performed in a 25 μl-volume tube at 60°C. The standard reaction mixture contains 3.2 μM each of TP and FP, 0.4 μM each of OP1 and OP2, 1.6 μM BP, 1.4 mM dNTPs, 5% dimethyl sulfoxide (DMSO), 20 mM Tris-HCl (pH 8.8), 10 mM KCl, 10 mM (NH₄)₂SO₄, 8 mM MgSO₄, 0.1% Tween 20, SYBR Green I (1/100,000-diluted), 40 units of Aac DNA polymerase, 1.5-2.4 μg of Taq MutS (optional) and 1 μl of blood or genomic DNA sample. Each reaction mixture should be incubated at 60°C for 40 - 60 minutes under isothermal conditions in a real-time PCR model Mx3000P system (Stratagene, La Jolla, CA, USA) where changes in the fluorescence intensity of SYBR Green I dye is monitored to detect the DNA amplification. Fig. 5 presents the results of the SmartAmp method when applied to detection of a clinically important SNP 460G>A in exon 7 of the human thiopurine S-methyltransferase (TPMT) gene. Clinical importance of this SNP will be discussed in the following section.

Fig. 5. Schematic illustration of the human TPMT gene and detection of the SNP 460G>A by the SmartAmp method. Two panels depict the time-courses of the SmartAmp assay reactions with TPMT-specific primers carrying WT (460G) or SNP (460A) alleles; namely, G/G homozygote and A/A homozygote.
3. Clinical applications of SmartAmp method

Hitherto, we have proven that the SmartAmp method is capable of detecting SNPs in drug transporter genes (e.g., ABCB1, ABCG2, and ABCC11) (Ishikawa et al., 2010; Aw et al., 2011; Ota et al., 2010; Toyoda et al., 2009) as well as in drug metabolizing enzyme genes, including those of cytochrome P450s, vitamin K epoxide reductase (VKORC1), and UDP-glucuronosyltransferase UGT1A1 (Aomori et al., 2009; Watanabe et al., 2007). Here we present other examples of SNP detection by the SmartAmp method, namely detection of genetic polymorphisms in human TPMT and ABCC4 genes to predict thiopurine-induced adverse reactions in certain sub-populations of patients.

3.1 Thioprine toxicity and genetic polymorphisms in TPMT gene

Thiopurines are effective immunosuppressants and anticancer agents used for treating childhood acute lymphoblastic leukemia, acute myeloblastic leukemia, autoimmune disease, rheumatoid arthritis, and inflammatory bowel diseases. The intracellular accumulation of such active metabolites as 6-thioguanine nucleotides (6-TGN), however, causes dose-limiting hematopoietic toxicity (Weinshilboum & Sladek, 1980). TPMT deficiency has been reported to exacerbate thiopurine toxicity (Fig. 6).

![Fig. 6. Cellular metabolism of azathioprine (AZA) and transport. HGRPT, hypoxanthine-guanine phosphoribosyltransferase; IMPDH, inosine monophosphate dehydrogenase; XO, xanthine oxidase. 6-MMP, 6-methylmercaptopurine; 6-MMPR, 6-methylmercaptopurine ribonucleosides; 6-MP, 6-mercaptopurine; 6-TGN, 6-thioguanine nucleotide; 6-TIMP, 6-thiosine 5’-monophosphate; 6-TU, 6-thiouric acid; 6-TXMP, 6-thioxanthosine monophosphate; GMPS, guanosine monophosphate synthetase; 6-TG, 6-thioguanine nucleotides. AZA is non-enzymatically converted to 6-MP in the cell. HGRPT is responsible for conversion of 6-MP to 6-TIMP. Thiopurine toxicity is caused by cellular accumulation of 6-TGN. Human ABC transporter ABCC4 plays a role of extruding the cytotoxic 6-TGN from the cells.](www.intechopen.com)
The enzyme TPMT operates in the main inactivation pathway for thiopurine drugs. The TPMT gene comprising 10 exons is located on chromosome 6p22.3 (Fig. 7). TPMT activity has been proven by numerous studies to be inversely correlated to 6-TGN levels in erythrocytes and other hematopoietic tissues (Krynetski et al., 1995; Evans, 2004; Anstey et al., 1992; Stolk et al., 1998; Yates et al., 1997; Black et al., 1998; Clunie et al., 2004). Polymorphisms in the TPMT gene can lead to intermediate, low, or no TPMT activity in certain patients, who are thus at an increased risk of developing thiopurine-induced life-threatening hematologic toxicity. Therefore, the thiopurine dose should be reduced by 50% for intermediate and by 80 to 90% for poor metabolizers to reduce the toxicity risk. There are a total of 24 functionally related alleles that have been reported to date, i.e., TPMT*1 to *18 and *20 to *23 (Schütz et al., 2000; Schaeffeler et al., 2008; Lee et al., 2008). TPMT*7 is the wild-type allele with high enzymatic activity. The TPMT*2 allele has one non-synonymous SNP of 238G>C (Ala80Pro). The TPMT*3A allele carries two non-synonymous SNPs of both 460G>A (Ala154Thr) and 719A>G (Tyr240Lys), while the TPMT*3B and TPMT*3C alleles each carry one non-synonymous SNP of 460G>A (Ala154Thr) and 719A>G (Tyr240Lys), respectively. While TPMT*2 is the first variant allele described, this allele is much less common than TPMT*3A. Population studies have shown that approximately 10% of Caucasians and African Americans inherit one non-functional TPMT*3A allele. This non-functional allele is not commonly seen in Asians. In Korean populations, TPMT*3C (0.88-2.54%) and *6 (0.25-1.27%) were found to some extents (Schaeffeler et al., 2008; Lee et al., 2008). Tai et al. reported that enhanced degradation of TPMT allozymes encoded by the TPMT*2 and TPMT*3 alleles is the mechanism for the decreased levels of TPMT protein and enzyme activity inherited as a result of these alleles (Tai et al., 1997). Subsequently, Wang et al. have demonstrated that the rapid degradation of TPMT*3A involves molecular chaperones, such as the heat shock proteins hsp70 and hsp90, and that TPMT*3A can also form intracellular aggresomes (Wang et al., 2003; Wang et al., 2005; Wang & Weinshilboum, 2006).

Fig. 7. The genomic organization of the human TPMT gene and five different alleles, i.e., TPMT*2, TPMT*3A, TPMT*3B, TPMT*3C, and TPMT*6. Non-synonymous SNPs of 238G>C (Ala80Pro), 460G>A (Ala154Thr), 539A>T (tyr180Phe), and 719A>G (tyr240Cys) are indicated by arrows.
3.2 SNP 2269G>A (Glu757Lys) in ABCC4 gene and thiopurine toxicity

For largely unknown reasons, there are subsets of Japanese patients who suffer from dose-limiting hematopoietic toxicity, but are not TPMT deficient (Takatsu et al., 2009). Recent studies have revealed that ABCC4 protects against thiopurine-induced hematopoietic toxicity by actively exporting thiopurine nucleotides (Krishnamurthy et al., 2008; Ban et al., 2010). ABCC4 is reportedly involved in the transport of antiviral agents, such as azidothymidine, adefovir, tenofovir, lamivudine, and ganciclovir (Shuetz et al., 1999; Adachi et al., 2002; Anderson et al., 2006; Imaoka et al., 2007), as well as anticancer drugs including 6-MP, 6-TG, methotrexate, and the camptothecins (Lee et al., 2000; Chen et al., 2002; Wielinga et al., 2002; Tian et al., 2005).

ABCC4 is a highly polymorphic gene with more than 20 missense genetic variants identified in the National Centre for Biotechnology Information (NCBI) database and the Pharmacogenetics Research Network (PGRN). Despite this situation, few data are available regarding the functions of these variants. Krishnamurthy et al. have recently shown that patients carrying SNP 2269G>A (Glu757Lys) in the human ABCC4 gene have severely reduced ABCC4 function resulting from an impairment of its cell membrane localization (Krishnamurthy et al., 2008). ABCC4 protects against thiopurine-induced hematologic toxicity by actively exporting 6-TGN, a toxic metabolite in the thiopurine drug metabolic pathway. Interestingly, the ABCC4 2269G>A SNP is common in the Japanese population (15 to 18% frequency), which suggests that this non-synonymous SNP could provide an explanation for the unsolved thiopurine toxicity that is not associated with genetic polymorphisms of TPMT (Takatsu et al., 2009; Ban et al., 2010; Ando et al., 2001).

Fig. 8. Schematic illustration of the human ABCC4 gene located on chromosome 13q32.1. The SNP 2269G>A that resides in exon 18 was detected by the SmartAmp method.
Unlike the situation for TPMT, the effects of the 2269G>A polymorphism in the \textit{ABCC4} gene have been relatively unexplored. Most recently, Ban \textit{et al.} have investigated an association between the 2269G>A polymorphism in the \textit{ABCC4} gene and thiopurine sensitivity in Japanese patients with inflammatory bowel disease (IBD) (Ban \textit{et al.}, 2010). A total of 235 samples from IBD patients were analyzed in their clinical study. They showed that the 6-TGN levels in red blood cells were significantly higher in patients with the allele of \textit{ABCC4} SNP 2269G>A than in patients with the wild-type allele ($P = 0.049$). The white blood cell count was significantly lower in patients with the SNP 2269G>A allele than in patients with the wild-type allele. Among 15 patients with leucopenia ($<3 \times 10^9/\text{l}$), seven carried the SNP 2269G>A allele (Ban \textit{et al.}, 2010). The odds ratio of carrying the SNP allele and having leucopenia was 3.33 (95% confidence interval 1.03-10.57, $P = 0.036$) (Ban \textit{et al.}, 2010). As compared with the azathiopurine (AZA) dose of 2 to 3 mg/kg recommended in Western countries (Lichtenstein \textit{et al.}, 2006), lower doses of AZA (0.6 to 1.2 mg/kg) are used in Japan because of the relatively higher sensitivity to AZA (Hibi \textit{et al.}, 2003). Those results strongly suggest that the \textit{ABCC4} SNP 2269G>A is a new diagnostic marker indicative of thiopurine toxicity/sensitivity in Japanese patients with IBD. In this context, the SmartAmp method for rapid detection of the \textit{ABCC4} SNP 2269G>A (Fig. 8) provides a practical tool for prediction of thiopurine toxicity/sensitivity in Japanese patients with IBD.

4. Conclusion

Accumulating evidence strongly suggests that genetic polymorphisms in drug metabolizing enzymes, transporters, receptors, and other drug targets (e.g., toxicity targets) are linked to inter-individual differences in the efficacy and toxicity of many medications. The genetic polymorphisms of drug metabolizing enzymes and transporters have been studied in many laboratories worldwide. In fact, efforts to discover and characterize gene polymorphisms resulted in new diagnostic tests for discriminating between different gene alleles and better strategies for pharmacotherapy.

To realize the promise of individualized medicine, however, genetic diagnosis should be further integrated with therapy for selecting drugs and treatments as well as for monitoring results. It is also critically important to reduce the cost of genetic diagnosis. Technologies are evolving to transform diagnostic devices for rapid genetic testing. Portable devices are being engineered for use in a range of settings to perform robust assays for the diagnosis of disease that will improve patient management, and result in greater convenience and speed to answer. Indeed, the POC diagnostics is a growing field that is gradually becoming more user-friendly with the introduction of portable devices and quicker nucleic acid detection.

The isothermal amplification technologies have a potential to cover different applications. A key requirement for the advancing personalized medicine resides in the ability of rapidly and conveniently testing patients’ genetic polymorphisms and/or mutations. With this respect, isothermal nucleic acid amplification technologies, including the SmartAmp method, are expected to translate into less complex and less expensive instrumentation.

5. Acknowledgment

The authors thank Prof. John D. Schuetz (St. Jude Children’s Hospital, Memphis, TN, USA) and Prof. Akira Andoh (Shiga University of Medical Science, Otsu, Japan) for their fruitful efforts.
discussion about genetic polymorphisms of human ABCC4 gene. Our thanks go to Drs. Alexander Lezhava and Wanping Aw (Omnics Science Center, RIKEN) for their generous support in SmartAmp-based genotyping experiments. The authors’ study was supported by a Japan Science and Technology Agency (JST) research project named “Development of the world’s fastest SNP detection system” (to TI) and Research Grant for RIKEN Omics Science Center from the Ministry of Education, Culture, Sports, Science and Technology (to YH).

6. References


Recent Advances in Pharmacogenomic Technology for Personalized Medicine


www.intechopen.com
In order to avoid late-stage drug failure due to factors such as undesirable metabolic instability, toxic metabolites, drug-drug interactions, and polymorphic metabolism, an enormous amount of effort has been expended by both the pharmaceutical industry and academia towards developing more powerful techniques and screening assays to identify the metabolic profiles and enzymes involved in drug metabolism. This book presents some in-depth reviews of selected topics in drug metabolism. Among the key topics covered are: the interplay between drug transport and metabolism in oral bioavailability; the influence of genetic and epigenetic factors on drug metabolism; impact of disease on transport and metabolism; and the use of novel microdosing techniques and novel LC/MS and genomic technologies to predict the metabolic parameters and profiles of potential new drug candidates.

How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
